Issuer: PRECISIS GmbH / Key word(s): Miscellaneous 22.11.2023 / 14:57 CET/CEST The issuer is solely responsible for the content of this announcement. Heidelberg, November 22nd 2023* — We are overjoyed to announce that PRECISIS GmbH has been not only nominated but has secured victory in the prestigious Innovation Award of the Federal State Baden-Württemberg 2023 on 21st of November 2023. This recognition fills us with immense pride and reinforces our dedication to pushing the boundaries of medical technology.
Read more about the Award here: https://wm.baden-wuerttemberg.de/index.php?id=15828 Our Innovation Journey Epilepsy affects approximately 1 to 3 percent of the population[1], and despite medical interventions, about 30 percent of patients continue to grapple with seizures[2]. I n response to this challenge, our dedicated team at PRECISIS GmbH has developed a groundbreaking neurostimulation device—an efficient brain stimulator designed to alleviate or remove the burden of symptoms for epilepsy patients. This unique stimulator is implanted directly under the scalp, allowing precise brain stimulation without any physical contact with the brain. The therapy is customizable and programmable via a tablet, ensuring a personalized treatment approach. Importantly, the patient experiences the therapy without any sensation of stimulation. see https://www.sciencedirect.com/science/article/abs/pii/S0011502903000658?via%3Dihub See https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498483/ Celebrations Winning in the Innovation Award of the Federal State Baden-Württemberg 2023 is a tremendous honor for us. This victory not only recognizes our commitment to innovation but also acknowledges the potential positive impact our technology could have on the lives of epilepsy patients. The Award Ceremony The winners were announced at a ceremony on November 21, 2023, hosted by the Ministry of Economic Affairs, Labor, and Tourism of Baden-Württemberg. This event took place at the House of Commerce in Stuttgart, and we were delighted to join this celebration of innovation. We extend our heartfelt gratitude to the esteemed judging panel for acknowledging our efforts. At PRECISIS GmbH, we are passionate about making a meaningful impact, and this victory serves as a testament to the dedication and hard work of our entire team. For media inquiries, please contact: Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T
A phase Ib/II study demonstrated that mosunetuzumab (Lunsumio) plus polatuzumab vedotin (Polivy) induced durable responses in patients with relapsed or refractory large B-cell lymphoma (LBCL),